Citalopram Treatment for Agitation in Alzheimer Dementia

阿尔茨海默氏痴呆（AD）患者的躁动是一个严重的公共卫生问题 for patients患者and carefully照顾者.激越的管理是治疗AD患者的主要优先事项。 非药物选择的有效性有限。几种药理学选择已经 但抗惊厥药、抗精神病药和胆碱酯酶抑制剂的研究结果令人失望 或与可疑的风险：效益比相关。需要更好的药物选择。选择性 5-羟色胺再摄取抑制剂（SSRIs），在这一领域研究不足，显示出作为治疗激动的希望 在AD中，基于AD中激越和脑5-羟色胺系统异常之间的联系的证据 患者，以及来自单中心、随机、安慰剂对照试验（RCT）的初步临床数据 其中西酞普兰上级优于奋乃静和安慰剂。现在需要进行一项明确的随机对照试验 研究SSRI治疗AD激越的有效性和安全性。为了进行这项研究， 西酞普兰治疗AD激越（CITAD）将召集研究者， 在正在进行的阿尔茨海默病抑郁症研究（DIADS-2）和 已完成的临床抗精神病药物试验的干预顽固性阿尔茨海默病（CATIE- AD）。CITAD将检查西酞普兰作为治疗临床显著 AD患者的焦虑。它还将调查药物基因组学，遗传学和临床预测因子， 对西酞普兰治疗的反应CITAD将是一项安慰剂对照、设盲、9周、8中心RCT 涉及200名AD患者它将招募来自真实的世界门诊、疗养院和 辅助生活设施。使用最先进的临床评级和新颖的每周护理电话 CITAD将检查西酞普兰对激越，其他神经精神症状， 认知、生活质量和日常功能。CITAD还将进行仔细的安全监测。这 这项研究非常重要，因为它将明确确定一种有前途的SSRI的疗效和安全性 作为AD中激越的治疗，这种疾病没有治疗选择，既被证明也没有 重大风险。如果西酞普兰被发现有效，它可能会成为一线治疗， 其他药理学选择的局限性。CITAD还将提供有关以下方面的重要知识： 反应的预测因子，并为未来的研究奠定基础，以了解参与的机制， 西酞普兰和其他SSRIs对激越的影响。阿尔茨海默氏痴呆症（AD）的躁动是一个严重的公共卫生问题， 对患者和护理人员的影响。管理躁动是一个主要的优先事项， 治疗AD患者。拟议的西酞普兰用于AD（CITAD）的激越将带来 在持续的大萧条中成功合作的研究人员在一起， 阿尔茨海默病研究（DIADS-2）和已完成的临床抗精神病试验 干预性阿尔茨海默病（CATIE-AD）。

Agitation in Alzheimer's dementia (AD) is a significant public health problem with serious consequences for patients and caregivers. The management of agitation is a major priority in treating patients with AD. Non-pharmacologic options have limited effectiveness. Several pharmacologic options have been explored, but findings for anticonvulsants, antipsychotics, and cholinesterase inhibitors are disappointing or associated with questionable risk:benefit ratio. Better pharmacologic options are needed. Selective serotonin reuptake inhibitors (SSRIs), understudied in this area, show promise as a treatment for agitation in AD, based on evidence of a link between agitation and brain serotonin system abnormalities in AD patients, and on preliminary clinical data from a single-site, randomized, placebo-controlled trial (RCT) in which citalopram was superior to perphenazine and placebo. A definitive RCT is now warranted investigating the efficacy and safety of an SSRI for agitation in AD . To carry out such a study, the proposed Citalopram for Agitation in AD (CITAD) will bring together investigators who have collaborated successfully in the ongoing Depression in Alzheimer's Disease Study (DIADS-2) and the completed Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE- AD). CITAD will examine the efficacy and safety of citalopram as treatment for clinically significant agitation in AD patients. It will also investigate pharmacogenomic, genetic, and clinical predictors of response to citalopram therapy. CITAD will be a placebo-controlled, masked, 9-week, 8-site RCT involving 200 patients with AD. It will enroll patients from real world outpatient, nursing home and assisted living settings. Using state of the art clinical ratings and novel weekly caregiver telephone ratings, CITAD will examine the effects of citalopram on agitation, other neuropsychiatric symptoms, cognition, quality of life, and daily functioning. CITAD will also conduct careful safety monitoring. This study is of great importance, as it will determine definitively the efficacy and safety of a promising SSRI as a treatment for agitation in AD, a condition with no treatment options that are both proven and without significant risk. Should citalopram be found effective, it will likely become a first line therapy, given the limitations of other pharmacologic options. CITAD will also provide significant knowledge about predictors of response, and lay the foundation for future studies to understand mechanisms involved in the effects of citalopram and other SSRIs on agitation. Agitation in Alzheimer's dementia (AD) is a significant public health problem with serious consequences for patients and caregivers. The management of agitation is a major priority in treating patients with AD. The proposed Citalopram for Agitation in AD (CITAD) will bring together investigators who have collaborated successfully in the ongoing Depression in Alzheimer's Disease study (DIADS-2) and the completed Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD).